Clinical Trial Update: MSCs in COVID-19 ARDS [Phase 3]

View source ↗

Summary

Phase 3 trial of mesenchymal stromal cells (Remestemcel-L) for COVID-19–related ARDS appears terminated.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Respiratory Distress Syndrome

Drugs mentioned

• Mesenchymal stromal cells
• Remestemcel-L (mesenchymal stromal cells)

Snippet

Sponsor: Icahn School of Medicine at Mount Sinai | Conditions: Mesenchymal Stromal Cells, Remestemcel-L | Phase 3 | Status: TERMINATED